Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from COSMO Pharmaceuticals N.V. ( (CH:COPN) ) is now available.
Cosmo Pharmaceuticals N.V. has announced the sale of its ‘Digital Trust’ division to Tinexta InfoCert for EUR 8.3 million as part of a strategic move to streamline its portfolio. This transaction aligns with Cosmo’s focus on growth in AI-powered medical devices and therapeutics, aiming to enhance its position as an innovation-driven healthcare company. By reallocating resources to core areas, Cosmo seeks sustainable growth and greater benefits for patients and shareholders.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF84.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a healthcare company focused on revolutionizing healthcare through innovative products that address unmet needs. Operating in Healthtech/AI, dermatology, gastroenterology, and contract manufacturing and development, Cosmo collaborates with global partners like Medtronic and Sun Pharma. Founded in 1997, the company is headquartered in Dublin, Ireland, with additional branches in the USA and Italy, employing approximately 330 people.
Average Trading Volume: 25,174
Current Market Cap: CHF948M
Learn more about COPN stock on TipRanks’ Stock Analysis page.